Table 1.
Characteristics of examined groups: breast cancer (BC-total) group of patients with selected subgroups for analysis, comparison group of subjects with benign breast lesions and control group of healthy women.
| Studied Group | Group Size | Menopausal Status | Age (Median) (Min–Max) |
TNM Status (Number of Incidents) |
Treatment (Number of Incidents) |
||
|---|---|---|---|---|---|---|---|
| Premeno-Pausal | Postmeno-Pausal | ||||||
| Preoperative group of patients | |||||||
| Breast cancer total group: | 100 | 11 | 89 | 60 (21–85) |
T1N0M0 (51) T1cN0M0 (3) T1N0Mx (2) T1NxM0 (9) T1N1M0 (1) |
T2N0M0 (24) T2NxM0 (4) T2N1M0 (4) T3N0M0 (1) T4N0M0 (1) |
BCT + ALND (69) BCT (4) Amputation + ALND (27) |
| Luminal A | 50 | 8 | 42 | 58 (21–81) |
T1N0M0 (27) T1N0Mx (2) T1cN0M0 (2) T1NxM0 (7) |
T2N0M0 (10) T2NxM0 (1) T3N0M0 (1) |
BCT + ALND (37) Amputation + ALND (13) |
| Luminal B | 50 | 3 | 47 | 62.5 (38–79) |
T1N0M0 (24) T1cN0M0 (1) T1NxM0 (2) T1N1M0 (1) |
T2N0M0 (14) T2NxM0 (3) T2N1M0 (4) T4N0M0 (1) |
BCT + ALND (32) BCT (4)Amputation + ALND (14) |
| Postoperative group of patients (matched pairs) | |||||||
| Breast cancer total group: | 43 | 3 | 40 | 61 (35–81) |
T1N0M0 (25) T1cN0M0 (1) T1N0Mx (1) T1NxM0 (4) |
T2N0M0 (8) T2NxM0 (2) T2N1M0 (1) T4N0M0 (1) |
BCT + ALND (33) Amputation + ALND (10) |
| Luminal A | 22 | 1 | 21 | 62 (35–81) |
T1N0M0 (13) T1N0Mx (1) T1cN0M0 (1) |
T1NxM0 (3)T2N0M0 (4) | BCT + ALND (19) Amputation + ALND (3) |
| Luminal B | 21 | 2 | 19 | 60 (38–79) |
T1N0M0 (12) T1NxM0 (1) T2N0M0 (4) |
T2NxM0 (2) T2N1M0 (1) T4N0M0 (1) |
BCT + ALND (14) Amputation + ALND (7) |
| Control groups | |||||||
| Benign breast lesion group | 50 | 12 | 38 | 50 (22–83) |
Fibroadenoma | N/A | |
| Healthy women group | 50 | 10 | 40 | 49.5 (25–69) |
N/A | N/A | |
ALND—axillary lymph node dissection; BCT—breast-conserving treatment; N/A—not applicable.